Evidence map›Paper›PMID 24936731›Full record

Trial reportArquivos brasileiros de endocrinologia e metabologia2014

Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.

Joelma Ines Tagliapietra Barros, Francisco Vagnaldo Fechine, Renan Magalhães Montenegro Júnior, Otoni Cardoso do Vale, Virgínia Oliveira Fernandes, Marcellus Henrique Loiola Ponte de Souza, Gilmara Holanda da Cunha, Manoel Odorico de Moraes, Catarina Brasil d'Alva, Maria Elisabete Amaral de Moraes

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Arquivos brasileiros de endocrinologia e metabologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04137328 (Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04137328 naunknown statusstarted 2019, after this paper: background citation

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Ran2019Enrolled60Registered outcomes3Posted comparisons0ConditionsDiabetic Neuropathic PainArmsInsulin, liraglutide
PMID 27186361PMID 29110715PMID 29416128PMID 29559450PMID 30320508PMID 26813032PMID 20359765PMID 28456941PMID 28608285other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joelma Ines Tagliapietra BarrosClinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Francisco Vagnaldo FechineClinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Renan Magalhães Montenegro JúniorDepartment of Community Health, School of Medicine, UFC, Fortaleza, CE, Brazil.
Otoni Cardoso do ValeDepartment of Clinical Medicine, School of Medicine, UFC, Fortaleza, CE, Brazil.
Virgínia Oliveira FernandesUniversity Hospital Walter Cantidio, UFC, Fortaleza, CE, Brazil.
Marcellus Henrique Loiola Ponte de SouzaDepartment of Physiology and Pharmacology, School of Medicine, UFC, Fortaleza, CE, Brazil.
Gilmara Holanda da CunhaDepartment of Nursing, UFC, Fortaleza, CE, Brazil.
Manoel Odorico de MoraesClinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Catarina Brasil d'AlvaClinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Maria Elisabete Amaral de MoraesClinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Universidade Federal do Ceará, Fortaleza, CE, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. MATERIALS AND

methodsInterventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).

resultsThere was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.

conclusionThe results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.

Indexed as

Activation, MetabolicAdultAlanine TransaminaseArea Under CurveAspartate AminotransferasesBlood GlucoseCholesterolDiabetes Mellitus, Type 2Evoked Potentials, SomatosensoryFastingFemaleFood, Formulatedgamma-GlutamyltransferaseGlucagon-Like Peptide 1Glycated HemoglobinHumansAlanine TransaminaseAspartate AminotransferasesBlood GlucoseCholesterolgamma-GlutamyltransferaseGlucagon-Like Peptide 1Glycated HemoglobinHypoglycemic AgentsPyrazinesSitagliptin PhosphateTriazolesTriglycerides

Identifiers

PMID24936731

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.